TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of HBeAg negative cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of HBsAg in liver tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of HBcAg in liver tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NK-activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SAEs associated with readmissions
Endpoint domain: Adverse events/effects
Primary endpoint: Lightness of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity after whitening
Endpoint domain: Adverse events/effects
Primary endpoint: Cocaine-positive urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Substance use outcomes
Primary endpoint: Self-reported cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Substance use outcomes
Primary endpoint: Sensitivity for diagnosis of acute colonic diverticulitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for diagnosis of acute colonic diverticulitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cohen's kappa coefficient for interobserver agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sinus opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell levels of CD3+ and CD4+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of INF‐γ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL‐2, IL‐10, and IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pentafecta rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative recovery of continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary nitrogen excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in hot flash severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median tissue TFV‐DP concentrations 14 days after TDF IVR placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable TFV‐DP DBS concentrations 14 days after TDF IVR placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection against ex‐vivo HIV challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood volume processed to reach target PLT yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median volume of ACD used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time needed for the procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants likely to accept the swine flu vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants reporting protective behaviours (e.g., carrying tissues, buying sanitising gel)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of 'very' or 'fairly' worried participants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological effectiveness of multi-site, multi-depth lateral branch blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cells stained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c target attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPG and PPG targets achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Tinnitus Handicap Inventory (THI) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasal resistances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciliated cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR Pedi 30 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first response to TOF nerve stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median clearance of mivacurium isomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean renal hemodynamic responses (para-aminohippurate clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in at least one of the four targeted women’s health issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: oral health literacy improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implementation of healthcare recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maintenance of physical health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood pressure fluctuation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Global Impression of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CGI-Improvement scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ADHD Index T scores of the CAARS-S
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Index T scores of the CAARS-O
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma DHEA-S levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Satisfaction with brow lines
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with distinct osteotomy lines
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eosinophil peak counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: median time to tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vertebral refractures
Endpoint domain: Mortality/survival
Primary endpoint: Daily crying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBC proteasome activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC proteasome activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in physical health factor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Potential lives saved
Endpoint domain: Mortality/survival
Primary endpoint: Cost associated with prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain after AT, CCM, or SCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discontinuation of the EAST secondary to pain
Endpoint domain: Adverse events/effects
Primary endpoint: THI-total scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: care seeking for diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antibiotic treatment for fast/difficult breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saving money during pregnancy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of hospital infection
Endpoint domain: Adverse events/effects
Primary endpoint: Reliance on vasoactive amines during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative atrial fibrillation (POAF)
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak angular velocity of anti-dystonic movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of pro-dystonic movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Enrichment of ox‐LDL in the intima
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Staining intensity in the intimal layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Staining intensity in the medial layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Homocyst(e)ine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to spontaneous breathing return
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to consciousness return
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to removal of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to operating room discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMERACT-OARSI responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of facial embodiment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence of AOM
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of antipyretic use
Endpoint domain: Adverse events/effects
Primary endpoint: Serum immunoglobulin G concentrations against pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: trends in glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tobacco consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcapillary escape rate of I-labeled albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: In-hospital cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: F concentration in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in FV servings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma adiponectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting Systolic Blood Pressure (RSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for additional measures to achieve hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: professional performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Weight of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy intake at meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRI signal pattern in putamen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Folate concentration in tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-MTHF/LV ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of response at 6 and 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement of dyspnea-related disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal Cell Carcinoma (BCC) incidence
Endpoint domain: Mortality/survival
Primary endpoint: Squamous Cell Carcinoma (SCC) incidence
Endpoint domain: Mortality/survival
Primary endpoint: Total perfusion defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ischemic perfusion defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cure rate of intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total effective rate of intestinal metaplasia treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success rate of smoking addiction treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-km time trial time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: running economy at low intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teachers' competence in providing asthma-related first aid interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel cleansing effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reducing the risk of early Lyme disease
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival at 6 months (OS-6)
Endpoint domain: Mortality/survival
Primary endpoint: Deep inhalation bronchoprotection to methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean fluoride concentration in enamel and dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anal incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rate of Alzheimer's disease (AD)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of night sweats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Green index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Positive Predictive Value (PPV) for high-grade lesions (CIN2-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival without neurodevelopmental impairment
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in nightly nocturia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for prosthetic interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Valsalva leak point pressure (VLPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first relapse of GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical improvement after shunt insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma active GLP-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma glucagon level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Paraplegia
Endpoint domain: Adverse events/effects
Primary endpoint: skin barrier function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin glossiness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall aesthetic improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: necrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ugly scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: screening time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inquiry about family supports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inquiry about housing conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Assessment (PGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Joint Assessment (PJA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Skin Assessment (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MPH
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete bolus transit (CBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Renal resistive index (RRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: passive range of arm motions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: basic arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20 response at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 50 response at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 70 response at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: cancellation rate before ovum retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum brain natriuretic peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ejection fraction (EF) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reductions in eating disorder risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-I serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IGFBP-3 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Young Mania Rating Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent weight gain > or =7% of baseline
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glasgow Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Manifest angle of strabismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement of paralytic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of critical events
Endpoint domain: Adverse events/effects
Primary endpoint: Hematocrit <45% without phlebotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nonpalpable spleen measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful improvements in pruritus, night sweats, and bone pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in indoor density of An. arabiensis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea score after 6-MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived effort after 6-MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to physical aspects
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: greater than a 2-line loss of vision from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RQ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CO2-excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: new bleeds or expansions
Endpoint domain: Adverse events/effects
Primary endpoint: symptomatic hemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: culture-proven bacterial meningitis or ventriculitis
Endpoint domain: Adverse events/effects
Primary endpoint: Total fluid gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes